RxDoctor Payments Data

Franklin Wefald, MD

Cardiovascular Disease · Smithfield, NCNPI 1306844832

Payments from drug & device makers

$12,369in general payments, 2019–2025

Across 605 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • United Therapeutics Corporation$833
  • Amgen$713
  • Axsome Therapeutics, Inc.$595
  • Johnson & Johnson$497
  • Novo Nordisk$479
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$9,48598%
  • Education$1532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca27$3,241
United Therapeutics Corporation69$833
Amgen70$713
Axsome Therapeutics, Inc.25$595
Johnson & Johnson37$497
Novo Nordisk30$479
GSK38$456
Actelion Pharmaceuticals US, Inc.17$434
Sanofi-aventis U.S. LLC14$367
Esperion Therapeutics, Inc.21$346
AbbVie16$328
Novartis22$320
Amarin Pharma, Inc.18$288
Paratek Pharmaceuticals, Inc.20$267
Bayer11$244
Lilly USA, LLC13$223
Abbott12$214
Teva Pharmaceuticals USA, Inc.13$200
Pfizer10$186
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)13$162
Baxter Healthcare5$156
Lundbeck LLC9$143
Shield Therapeutics Inc2$134
E.r. Squibb & Sons, L.L.C.10$133
Boehringer Ingelheim7$120
Kowa Pharmaceuticals America, Inc.8$105
Mallinckrodt Hospital Products Inc.4$93
Bristol Myers Squibb5$91
Phathom Pharmaceuticals, Inc.4$86
Otsuka America Pharmaceutical, Inc.5$86
Biohaven Pharmaceutical Holding Company Ltd.5$71
Mylan Specialty L.p.4$60
Sunovion Pharmaceuticals Inc.3$59
Inspire Medical Systems, Inc.2$54
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$53
Merck3$50
Kiniksa Pharmaceuticals, Ltd.2$47
Edwards Lifesciences2$33
Tolmar, Inc.1$31
Polarityte, Inc.2$30
Arbor Pharmaceuticals, Inc.2$25
Biodelivery Sciences International, Inc.2$24
Lexicon Pharmaceuticals, Inc.1$24
Redhill Biopharma Inc.1$23
Gilead1$22
Eisai Inc.1$20
Infobionic, Inc2$18
Philips North America LLC1$18
Irhythm Technologies, Inc.1$17
Dexcom, Inc.1$17
Scpharmaceuticals Inc.1$17
Agepha Pharma FZ LLC1$17
Idorsia Pharmaceuticals US Inc1$16
Advanced Oxygen Therapy Inc.1$16
Vertex1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$14
Siemens Medical Solutions USA, Inc.1$13
Circassia Inc.1$13
Regeneron Healthcare Solutions, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,369 in reported general payments places this provider in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$690,269
Medicare patients
315
Services billed
7,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban505$334,247
XareltoRivaroxaban382$262,434
JardianceEmpagliflozin347$229,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter262$201,553
TrulicityDulaglutide135$192,922
OzempicSemaglutide156$191,663
Cosentyx Sensoready PenSecukinumab13$180,064
MounjaroTirzepatide151$167,433
Repatha SureclickEvolocumab214$158,920
EntrestoSacubitril/Valsartan177$146,211
OpsumitMacitentan11$141,765
NuzyraOmadacycline Tosylate15$92,693
Nurtec OdtRimegepant Sulfate59$87,215
BrilintaTicagrelor121$68,824
MultaqDronedarone Hcl64$58,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$186$421,462564 claims
Lilly USA, LLCTrulicity, Mounjaro$223$360,355286 claims
Johnson & JohnsonXarelto$497$262,434382 claims
Boehringer IngelheimJardiance, Combivent Respimat$120$254,442383 claims
Novo NordiskOzempic, Rybelsus, Wegovy$479$240,761198 claims
GSKTrelegy Ellipta, Anoro Ellipta$456$222,428288 claims
NovartisEntresto$320$146,211177 claims
Actelion Pharmaceuticals US, Inc.Opsumit$434$141,76511 claims
AstraZenecaBrilinta, Farxiga$3,241$97,937159 claims
Paratek Pharmaceuticals, Inc.Nuzyra$267$92,69315 claims
AbbVieLinzess, Vraylar$328$58,71486 claims
Sanofi-aventis U.S. LLCMultaq$367$58,44564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Smithfield

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →